Medincell SA
PAR:MEDCL

Watchlist Manager
Medincell SA Logo
Medincell SA
PAR:MEDCL
Watchlist
Price: 13.62 EUR 4.29% Market Closed
Market Cap: 450.4m EUR

Intrinsic Value

The intrinsic value of one MEDCL stock under the Base Case scenario is 21.85 EUR. Compared to the current market price of 13.62 EUR, Medincell SA is Undervalued by 38%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

MEDCL Intrinsic Value
21.85 EUR
Undervaluation 38%
Intrinsic Value
Price
Base Case Scenario

Valuation History
Medincell SA

MEDCL
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for MEDCL cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Medincell SA
PAR:MEDCL
FR
Pharmaceuticals
Market Cap
450.4m EUR
IPO
Oct 8, 2018
FR
Pharmaceuticals
Market Cap
450.4m EUR
IPO
Oct 8, 2018
Price
€false
EPS
€false
Company Overview
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about MEDCL?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Medincell SA
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Medincell SA

Current Assets 47.8m
Cash & Short-Term Investments 38.9m
Receivables 7.1m
Other Current Assets 1.8m
Non-Current Assets 11.1m
Long-Term Investments 3.3m
PP&E 5.2m
Intangibles 2.6m
Other Non-Current Assets -1k
Efficiency

Free Cash Flow Analysis
Medincell SA

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Medincell SA

Revenue
10.7m EUR
Cost of Revenue
-896k EUR
Gross Profit
9.8m EUR
Operating Expenses
-29.3m EUR
Operating Income
-19.5m EUR
Other Expenses
-11.9m EUR
Net Income
-31.4m EUR
Fundamental Scores

MEDCL Profitability Score
Profitability Due Diligence

Medincell SA's profitability score is 48/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Positive Gross Profit
Exceptional Revenue Growth Forecast
Exceptional ROE
48/100
Profitability
Score

Medincell SA's profitability score is 48/100. The higher the profitability score, the more profitable the company is.

MEDCL Solvency Score
Solvency Due Diligence

Medincell SA's solvency score is 33/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Positive Net Debt
Long-Term Solvency
33/100
Solvency
Score

Medincell SA's solvency score is 33/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MEDCL Price Targets Summary
Medincell SA

Wall Street analysts forecast MEDCL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MEDCL is 22.25 EUR with a low forecast of 18.48 EUR and a high forecast of 26.25 EUR.

Lowest
Price Target
18.48 EUR
36% Upside
Average
Price Target
22.25 EUR
63% Upside
Highest
Price Target
26.25 EUR
93% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Medincell SA
does not pay dividends
Shareholder Yield

Current shareholder yield for MEDCL is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

MEDCL Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one MEDCL stock?

The intrinsic value of one MEDCL stock under the Base Case scenario is 21.85 EUR.

Is MEDCL stock undervalued or overvalued?

Compared to the current market price of 13.62 EUR, Medincell SA is Undervalued by 38%.

Back to Top